Site-specific DNA methylation contributes to neurotensin/ neuromedin N expression in colon cancers. Am J Physiol Gastrointest Liver Physiol 279: G1139-G1147, 2000.-The neurotensin/neuromedin N (NT/N) gene is expressed in fetal colon, repressed in newborn and adult colon, and reexpressed in ϳ25% of colon cancers. Our purpose was to determine the effect of gene methylation on NT/N silencing in colon cancers. We found that the NT/N gene was expressed in human colon cancer cell line KM12C but not in KM20 colon cancer cells. Bisulfite genomic sequencing demonstrated that all CpG dinucleotides in the region from Ϫ373 to ϩ100 of the NT/N promoter, including a CpG site in a distal consensus AP-1 site, were methylated in KM20 but unmethylated in KM12C cells. Treatment of KM20 cells with demethylating agent 5-azacytidine induced NT/N expression, suggesting a role for DNA methylation in silencing of NT/N in colon cancers. To better elucidate the mechanisms responsible for NT/N repression by DNA methylation, we performed gel shift assays using an oligonucleotide probe corresponding to the distal AP-1 consensus sequence of the NT/N promoter. Methylation of the oligonucleotide probe inhibited protein binding to the distal AP-1 site of the NT/N promoter, suggesting a potential mechanism of NT/N gene repression in colon cancers. We show that DNA methylation plays a role in NT/N gene silencing in the human colon cancer KM20 and that NT/N expression in KM12C cells is associated with demethylation of the CpG sites. DNA methylation likely contributes to NT/N gene expression noted in human colon cancers. gene expression; colon cancer cells NEUROTENSIN (NT) is a tridecapeptide originally isolated from bovine hypothalami by Carraway and Leeman (9) and subsequently localized to specialized enteroendocrine cells (N cells) of the adult small bowel (reviewed in Ref. 45). NT has numerous physiological functions in the gastrointestinal tract, including stimulation of pancreatic secretion and colonic motility, inhibition of gastric and small bowel motility, and stimulation of pancreatic, small bowel, and colonic growth (1, 3, 11, 18, 19, 25, 51) . Expression of the gene encoding NT and the structurally-related hexapeptide neuromedin N (designated NT/N) is developmentally regulated in the small intestine of both rats and humans in a distinctive temporal-and spatial-specific distribution (17, 20, 40) .
gene expression; colon cancer cells NEUROTENSIN (NT) is a tridecapeptide originally isolated from bovine hypothalami by Carraway and Leeman (9) and subsequently localized to specialized enteroendocrine cells (N cells) of the adult small bowel (reviewed in Ref. 45) . NT has numerous physiological functions in the gastrointestinal tract, including stimulation of pancreatic secretion and colonic motility, inhibition of gastric and small bowel motility, and stimulation of pancreatic, small bowel, and colonic growth (1, 3, 11, 18, 19, 25, 51) . Expression of the gene encoding NT and the structurally-related hexapeptide neuromedin N (designated NT/N) is developmentally regulated in the small intestine of both rats and humans in a distinctive temporal-and spatial-specific distribution (17, 20, 40) .
In the human colon, NT/N is expressed in the fetus during midgestation when the colon is similar to the small bowel from a morphological and functional standpoint; NT/N expression is not apparent in the colon of the newborn or the adult but is reexpressed in ϳ25% of colon cancers (20, 24) . Previously, we have shown that constitutive (i.e., basal) NT/N expression in the endocrine cell line BON is highly dependent on the binding of transcription factors to a proximal promoter region located 50 bp upstream of the transcriptional start site (22) . In contrast, Kislauskis and Dobner (33) have shown that a distal consensus activator protein (AP)-1 site is crucial for NT/N induction in the PC12 cell line, which does not constitutively express NT/N. Therefore, it appears that the induction of NT/N expression in nonexpressing cells is highly dependent on an intact distal AP-1 promoter element. In addition, it is likely that other genetic factors contribute to the complex pattern of NT/N expression noted in normal tissues and in some cancers.
DNA methylation appears to play a critical role in the expression of a number of genes during normal development and with malignant transformation (10, 16, 50) . The natural substrates of the mammalian methyltransferase enzyme are the cytosines within the dinucleotide CpG (10, 16, 50) . Methylation of cytosines in the CpG sequence is thought to ensure the silencing of certain tissue-specific genes in nonexpressing cells (10, 16 ). The precise spatial and temporal pattern of gene expression noted during development in certain tissues is thought to depend, in large part, on the gene methylation pattern, with demethylation of tissue-specific genes noted in the cell types in which they are expressed (2, 31, 50) . Furthermore, alterations of DNA methylation, which can affect patterns of gene expression important for cell growth, occur in a number of human cancers, including colon cancers (35, 49) . A mechanism that is increasingly being recognized as important for methylation-mediated gene silencing is the interference of transcription factor binding to the gene promoter (16, 50) . Such interference has been noted for a number of known transcription factors, including AP-2, E2F, nuclear factor-B, and cAMP response element binding protein (CREB)/activating transcription factor (ATF) (5, 6, 13, 27, 28) . Promoter methylation may contribute to the gene expression pattern of tissue-specific genes (16, 50) .
Previously, we have shown that NT/N expression is induced in the liver cancer cell line HepG2 by treatment with the demethylating agent 5-azacytidine (5-azaC) (15) . Moreover, in vitro methylation of the NT/N promoter markedly inhibited NT/N promoter activity in HepG2 cells. These findings implicate DNA methylation in the expression of NT/N noted in certain ectopic tissues, such as hepatic-derived cells. However, the mechanisms contributing to NT/N repression by DNA methylation are not known. Furthermore, the role that DNA methylation plays in the expression of NT/N in other ectopic tissues, such as colon cancers, has not been determined. Therefore, the purpose of this study was twofold: 1) to determine whether methylation may play a role in NT/N gene expression in colon cancers and 2) to better elucidate the mechanisms contributing to NT/N expression with the use of a sensitive bisulfite sequencing technique, locus accessibility assays, and gel shift analyses.
MATERIALS AND METHODS

Materials.
Restriction, ligation, and other DNA-modifying enzymes were purchased from Promega (Madison, WI), Stratagene (LaJolla, CA), or New England Biolabs (Beverly, MA). PCR materials and Taq DNA polymerase were from Promega. Oligo(dT) cellulose (type III) was obtained from Collaborative Research (Bedford, MA), and radioactive compounds were obtained from New England Nuclear (Boston, MA). Nucleotides and poly(dI ⅐ dC) were purchased from Pharmacia LKB Biotechnology (Piscataway, NJ). Tissue culture media and reagents were obtained from GIBCO BRL (Grand Island, NY). All other reagents were of molecular biology grade and were either obtained from Sigma Chemical (St. Louis, MO) or Amresco (Solon, OH). Nitrocellulose filters were from Schleicher & Schuell (Keene, NH). Ribonuclease (RNase) protection experiments were performed using the RPA-II kit from Ambion (Austin, TX). To determine the relative size of the protection products, RNA markers (Ambion) transcribed with T7 RNA polymerase were run in parallel lanes. The constitutively expressed human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was obtained from Ambion and used to ensure integrity of the RNA samples analyzed by both Northern blot and RNase protection. The pGEM-Zf vector as well as oligonucleotides containing AP-1, glucocorticoid response element (GRE), and Sp1 consensus sites were purchased from Promega. The oligonucleotides containing c-myc and Oct-1 consensus sites were from Oncogene Science (Cambridge, MA) and Stratagene, respectively. The oligonucleotides corresponding to the wildtype sequences of NT/N promoter were synthesized by Oligos Etc. (Wilsonville, OR).
Cell culture. The human colon cancer cell lines KM20 and KM12C were obtained from Dr. Isaiah J. Fidler (M. D. Anderson, Houston, TX) (38, 39) and cultured in MEM plus 1 mmol/l sodium pyruvate, 1ϫ solution of MEM nonessential amino acid, 2ϫ solution of MEM nonessential vitamin mixture, and 10% fetal bovine serum (FBS). The human cell line BON, which was established in our laboratory from a pancreatic carcinoid tumor (21, 44) , was cultured in DMEM and F12K at 1:1 supplemented with 5% FBS. All cells were maintained in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
RNA extraction, Northern blot, ribonuclease protection, and RT-PCR. Cells were harvested and RNA was obtained by the method of Schwab et al. (48) , except that digestion with proteinase K was for 1-2 h at 50°C. Polyadenylated RNA was then selected from all samples by oligo(dT) cellulose column chromatography, and the final RNA concentration was quantified spectrophotometrically.
For Northern blot analysis, polyadenylated RNA was electrophoresed in 1.2% agarose-formaldehyde gels, transferred to nitrocellulose, and hybridized with a cRNA probe (pHNT E0.9) containing 806 bp of the human NT/N gene subcloned into the EcoR I site of a pGEM4 vector (4) . Hybridization and washing conditions were as described previously (23, 38) . Blots were stripped and reprobed with the constitutively expressed human GAPDH gene. RNase protection analyses were performed as described previously (23, 38) using the RPA-II kit according to the instructions of the supplier. For RT-PCR, two primers were used: P 1 was 5Ј-GATGATG-GCAGGAATGAAAATCCAG-3Ј (located in the first exon) and P 2 was 5Ј-TGGTAAAAGCCCTGCTGTGACAGA-3Ј (located in the third exon). The RT-PCR was performed as described previously (38) .
Cytosine deamination-PCR. Cytosine deamination by bisulfite treatment of single-stranded DNA and subsequent PCR amplification was performed essentially as described by Frommer et al. (26) . Genomic DNA (20 g) was first digested with EcoR I, denatured in 0.3 M NaOH for 20 min at 37°C in a volume of 100 l, added to 1.1 ml of deamination buffer containing 2.2 M Na 2 S 2 O 5 and 1 mM hydroquinone (pH 5.0), and then incubated at 55°C for 16 h. The DNA was desalted by dialyzing at 4-10°C against 2 liters of 5 mM NaAc (pH 5.2), 0.5 mM hydroquinone, 0.5 mM NaAc (pH 5.2), and H 2 O. Samples were concentrated in a vacuum desiccator, denatured with 0.3 M NaOH for 20 min at 37°C, neutralized with 3 M ammonium acetate (pH 7.0), and precipitated with ethanol. An aliquot of DNA was amplified with modified primers. All reactions were carried out in 100-l volumes containing 1ϫ PCR buffer, 1.5 mM MgCl 2 , 0.2 mM dNTP (each), 20 pmol primers, and 2.5 units Taq DNA polymerase. The samples were then subjected to 35 cycles of amplification consisting of 1-min denaturation at 94°C, 45-s annealing at 58°C, and 1.5-min extension at 72°C, followed by an additional extension step at 72°C for 10 min. The amplified fragments were cloned into a pGEM5-Zf vector, and then at least 18 independent clones for each fragment were sequenced using T7 and Sp6 primers to determine the methylation pattern of individual molecules. Primers, chosen on the basis of the human genomic sequence, correspond to the following regions of the human NT/N gene (4): positions Ϫ339 to Ϫ311 bp and ϩ102 to ϩ130 bp for the amplification of upper strand and positions Ϫ373 to Ϫ345 bp and ϩ134 to ϩ158 bp for the lower strand. The modified primers were P U1 (5Ј-GTTTGGAGTGGGGGAATGAGAAGTG-3Ј) and P U2 (5Ј-ATTGAATTTTGATTCCTACCATCATCTT-3Ј) for the upper strand and P L1 ( 5Ј-GAATCTCATATTTCACAAAATCAAA-ATA-3Ј) and P L2 (5Ј-GAAGTTAGGAGTAGTATGTATATA-AGT-3Ј) for the lower strand.
Nuclear accessibility assays. Nuclei were isolated from KM20 and KM12C and digested with EcoR I or Msp I at various concentrations. All digestions were terminated by addition of 10 mM EDTA, 0.5% SDS, and 600 g/ml proteinase K at 55°C for 4 h. DNA was prepared by organic extraction and ethanol precipitation. DNA samples were restricted with Hind III, and fragments were separated overnight by electrophoresis through a 1% agarose gel with constant volt-age (1.5-2 V/cm). After electrophoresis, the gel was soaked in 0.25 mol/l HCl for 10 min and rinsed briefly with deionized water. The DNA was denatured, neutralized, and transferred to nitrocellulose filters and then hybridized with the human NT/N DNA fragment containing the first exon, first intron, and second exon.
Electrophoretic mobility shift assays. KM20 and KM12C cell nuclear extracts were prepared according to the method of Dignam et al. (14) or Schreiber et al. (47) . Synthetic oligonucleotides corresponding to the upper and lower strands of wild-type NT/N promoter sequence (Ϫ245 to Ϫ224) containing the distal consensus AP-1 site were synthesized, annealed, and labeled with [␥-32 P]ATP and T4 polynucleotide kinase. Electrophoretic mobility shift assays (EMSAs) were performed as described previously (22) . The reaction mixtures contained 40,000 cpm (ϳ4 fmol) of 32 P end-labeled mock methylated or methylated oligonucleotide (methylated with Sss I methylase) and 10-20 g nuclear protein in a final volume of 20 l of 12.5 mM HEPES (pH 7.9), 100 mM KCl, 10% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 2 g BSA, and 3 g poly(dI ⅐ dC) as nonspecific competitors. The reaction was incubated for 20 min at room temperature. Competition binding experiments were performed by first incubating the competitor fragment, in molar excess, with the nuclear protein and binding buffer for 10 min on ice. The labeled probe was then added, and incubation continued for 20 min at room temperature. The reaction mixtures were loaded onto 6% nondenaturing polyacrylamide gels and resolved by electrophoresis at 250 V for 2-3 h. The gels were subsequently dried and autoradiographed at Ϫ70°C.
RESULTS
The NT/N gene is expressed in the KM12C colon cancer line but not in KM20 cells. We have previously shown that NT/N is expressed in ϳ25% of colon cancers examined (24) . This expression pattern appears random, with no relation to tumor site or stage. To better determine the mechanisms for NT/N expression in these "ectopic" tissues, we analyzed the two human colon cancer cell lines KM12C and KM20. We found that NT/N is expressed in KM12C cells, as noted by Northern blot (Fig. 1A) . The BON cell line, which we have previously shown expresses the NT/N gene and secretes NT peptide (21, 44) , was used as a positive control. In contrast, NT/N expression was not noted in the KM20 colon cancer cell line. To ensure intact RNA samples, the blot was reprobed with the constitutively expressed GAPDH gene, which was noted in all three cell lines.
As confirmation of NT/N expression in KM12C cells, RNA was analyzed by both RNase protection and RT-PCR. The expected 180-base NT/N protection product, corresponding to exon 1, was noted in KM12C cells and the positive control BON but not in KM20 cells (Fig.  1B) . Similarly, RT-PCR failed to detect the expression of NT/N in KM20 cells; the predicted fragment of ϳ380 bp was noted in both KM12C and BON (Fig. 1C) . Together, these results identify NT/N expression in the KM12C colon cancer cell line but not in KM20 cells.
Analysis of the CpG sites in the human NT/N promoter. Previously, we have shown that the proximal promoter region of the NT/N gene is sufficient for basal promoter activity (22) . To determine whether methylation may contribute to the NT/N expression noted in colon cancers, we evaluated the region from Ϫ373 to ϩ100 bp of the human NT/N gene for potential CpG dinucleotides, which are natural substrates of mammalian methyltransferase (16, 50) . Three CpG sites are located in this region ( Fig. 2A) . Interestingly, one CpG site, located at position Ϫ232, is contained within the consensus sequence of a distal AP-1 site (TGCGTCA), which is crucial for induction of the rat NT/N gene in the PC12 neuronal cell line (33) . The second site (Ϫ190) is located in a CRE half-site (CGTCA), and the third site (ϩ83) is located in the untranslated region of the first exon.
We next used a genomic sequencing method for analysis of the methylation pattern (26) . Two sets of primers, each specific for the upper (P U1 and P U2 ) and lower (P L1 and P L2 ) strands of bisulfite-treated human genomic DNA, were designed for the analysis of the methylation status of the NT/N gene. The plasmid clones derived from each cell line were analyzed by DNA sequencing. This technique relies on deamination of cytosine, but not methylcytosine, to uracil by bisulfite in single-stranded DNA (12, 26, 30, 42, 52 ). Following PCR amplification, cloning, and conventional dideoxy sequencing, methylcytosine residues were identified as cytosines in the sequence ladder. Typical sequence profiles are shown in Fig. 2B . The analysis of plasmid clones derived from the upper strands demonstrated that all three CpG sites were methylated in KM20 cells and unmethylated in KM12C and BON cells. Analysis of the lower strands demonstrated identical results (data not shown). These findings suggest that demethylation of the CpG dinucleotides in the promoter region may be important for the expression of NT/N in certain cells. Therefore, DNA methylation may play a role in the repression of the NT/N gene in KM20 cells.
DNA methylation plays a role in NT/N gene expression.
To determine the role of DNA methylation in the expression of NT/N in these colon cancer cells, KM20 cells were treated with the demethylating agent 5-azaC (29, 34) at a concentration of 8 M for 4 days and then changed to fresh media for an additional 4 days. RNA was analyzed by RNase protection assays (Fig. 3A) . Treatment of KM20 cells with 5-azaC resulted in the induction of NT/N expression. We also treated KM12C cells with 5-azaC and then determined whether NT/N expression was altered using RT-PCR; GAPDH was amplified in the same reaction vessels (Fig. 3B) . As expected, 5-azaC had no apparent effect on NT/N expression. Untreated BON cells were used as a positive control for NT/N expression. Therefore, these findings suggest that demethylation of the CpG sites by 5-azaC results in NT/N gene induction in KM20 cells. Conversely, NT/N expression in KM12C is not affected by 5-azaC since the CpG sites are unmethylated.
To confirm that treatment with 5-azaC results in demethylation of the CpG sites in the NT/N gene, we again used a genomic sequencing method to analyze DNA from KM20 cells that were either treated with 5-azaC or untreated (Fig. 4) . All three CpG sites were unmethylated in KM20 cells after 5-azaC treatment. Together, these results provide further evidence that DNA methylation plays a role in the repression of the NT/N gene in the human colon cancer cell line KM20.
One potential mechanism by which DNA methylation can suppress gene expression is alteration of the chromatin structure, thus influencing gene accessibility (16, 36, 50) . Therefore, locus accessibility assays were performed using nuclei isolated from KM12C and The TATATA box is indicated by the under-and overlines, and the ATG translational initiation codon is indicated by the underline. B: methylation analyses of clones derived from the upper strand of the proximal human NT/N promoter. Genomic DNA from KM20, KM12C, and BON cells was treated with sodium bisulfite, amplified, and cloned into the pGEM5-Zf vector. Primers (P U1 and P U2 ) to the NT/N upper strand were used in the PCR reaction as described in MATERIALS AND METHODS. Unmethylated Cs were converted to Ts in the KM12C and BON cell clones, whereas methylated Cs remained as Cs at sites Ϫ232 and Ϫ190 (P U1 primer) and ϩ83 (P U2 primer) in the KM20 cell clones (arrows). KM20 cells treated with either EcoR I or Msp I restriction enzymes (37) (Fig. 5 ). Our results with either restriction enzyme did not reveal significant differences in the digestion profiles of either KM12C or KM20 cells, suggesting that the overall chromatin structure is similar, although the methylation status of the promoter is different in these cell lines.
DNA methylation inhibits the binding of transcription factors to a distal consensus AP-1 site in the NT/N promoter.
We next determined whether methylation suppresses NT/N gene expression by preventing the binding of transcription factors to the promoter. To assess this possibility, an oligonucleotide corresponding to the wild-type NT/N sequence (Ϫ245 to Ϫ224) containing the distal consensus AP-1 site was synthesized and used in EMSAs with nuclear extracts from the KM12C cell line. When the human NT/N (hNT/N) promoter fragment was used as a probe, a DNA-protein binding complex was demonstrated that was effectively inhibited by unlabeled human NT/N and an oligonucleotide containing an AP-1 consensus sequence (Fig. 6A) . In contrast, the complex was not affected by a molar excess of oligonucleotides containing either GRE or c-myc consensus sites. These findings demonstrate the binding of AP-1 proteins to this NT/N promoter region, as shown by the competition experiment using the AP-1 oligonucleotide probe; the absence of competition using the GRE and c-myc probes indicates that the binding is specific and is not competed by unrelated nucleotide sequences.
To further assess the role of methylation in protein binding to the NT/N promoter fragment, the NT/N oligonucleotide was methylated by Sss I methylase and labeled, and the EMSA was repeated using KM12C nuclear extracts (Fig. 6B) . Methylation of the NT/N probe effectively prevented the binding of AP-1 proteins compared with the specific binding noted with the unmethylated probe. As a control for the specificity of the methylation results using the NT/N promoter fragment, nonspecific oligonucleotides containing either consensus Sp1 or Oct-1 sites were methylated and labeled, and the EMSA was repeated with KM12C extracts. Methylation of these probes did not alter the binding pattern of Sp1 or Oct-1 proteins to their consensus binding sites. Protein binding, however, was effectively competed using the unlabeled probe in molar excess. Together, these findings suggest that DNA methylation effectively blocks protein binding to this distal AP-1 promoter sequence and may explain the gene silencing noted in the KM20 cell line in which this CpG site is methylated. 
DISCUSSION
In this study, we demonstrated that the terminally differentiated endocrine gene NT/N is constitutively expressed in the human colon cancer cell line KM12C but not in KM20 cells. Consistent with these results, we have previously shown that NT/N is expressed in the fetal colon, repressed in the newborn and adult colon, and then reexpressed in ϳ25% of human colorectal cancers (8, 24) . The mechanisms underlying this pattern of NT/N gene silencing in normal adult tissues with selective reexpression in a minority of colorectal cancers have not been determined. Delineating the cellular mechanisms contributing to the complex pattern of NT/N expression will provide a better understanding of factors regulating differentiated gene expression associated with normal intestinal development and malignant transformation.
Previously, we have shown that NT/N expression is induced in the HepG2 hepatocellular cancer by treatment with the potent demethylating agent 5-azaC (15) . Moreover, in vitro methylation of the NT/N promoter markedly inhibited its activity in the HepG2 cell line, thus further supporting a role for gene methylation in the expression of NT/N in certain ectopic tissues. Therefore, our present study was performed to determine whether similar mechanisms may explain the selective expression of NT/N in only certain colorectal cancers. We found that KM20 cells, in contrast to the KM12C cell line, do not express the NT/N gene as assessed by Northern blot and sensitive RNase protection and RT-PCR analyses. However, treatment of (lanes 2-5) . Protein binding is noted to the labeled hNT/N probe, which is effectively competed using either unlabeled hNT/N or AP-1. B: labeled hNT/N oligonucleotide probe was either methylated (M ϩ ) or unmethylated (M Ϫ ) and analyzed by mobility shift assays with the use of KM12C protein extracts. Methylation of the labeled probe inhibits protein binding to the AP-1 site. C: As a control for the specificity of the gel shift results, labeled oligonucleotides containing consensus Sp1 or Oct-1 sites were either methylated or unmethylated and analyzed by mobility shift assays using KM12C protein extracts. No significant effect on the binding pattern was noted with methylation of either the Sp1 or Oct-1 oligonucleotides. Competition experiments were performed using a 100-fold molar excess of unlabeled oligonucleotide. KM20 cells with 5-azaC resulted in NT/N gene activation, suggesting that gene methylation may be responsible for the NT/N gene silencing noted in KM20 cells. Therefore, these results provide direct evidence that the repressed NT/N gene can be reactivated by the inhibition of DNA methylation.
Genes with tissue-specific expression patterns often have methylated CpGs within the promoter region (16, 31, 50, 52) . We next performed nucleotide sequence analysis of the NT/N proximal promoter sequences and demonstrated three CpG dinucleotides in the region from Ϫ373 to ϩ100, which has previously been shown to be sufficient for both basal and induced NT/N expression (22, 33) . As a further assessment of the role of DNA methylation in NT/N expression, we performed genomic sequencing after bisulfite treatment, which results in deamination of unmethylated cytosines, identified as thymines, but with no change in the methylated cytosines (12, 30, 42, 52) . Analysis of DNA methylation by bisulfite sequencing allows the detection of methylation at a greater number of cytosines and with higher resolution than analysis with methylation-sensitive enzymes (52) . Moreover, this technique has been used to assess methylation patterns in other tissue-specific genes, such as tyrosine hydroxylase, galectin-1, prolactin, and growth hormone (42, 43, 46) . We found that all three of the CpG doublets in the region from Ϫ373 to ϩ100 are methylated in KM20 cells and demethylated in KM12C and BON cells. Interestingly, one of the CpG sites methylated in the KM20 cell line is contained within an AP-1 consensus site that is critical for induction of the rat NT/N gene in response to various environmental influences. Kislauskis and Dobner (33) noted that this site served as a functional focal point for NT/N gene induction in PC12 rat neuronal cells. Since one of the mechanisms by which methylation can suppress gene expression is by directly preventing the binding of transcription factors (5, 6, 13, 16, 27, 28, 50), we next determined whether DNA methylation alters protein binding to this distal AP-1 site. Methylation of the human NT/N promoter fragment inhibited the binding to the labeled probe. Previously, we have shown that methylation of the NT/N promoter in vitro resulted in a marked reduction of NT/N promoter activity to baseline levels in transfected liver cancer cell lines (15) . Collectively, these results provide additional evidence to support the notion that DNA methylation results in NT/N gene silencing by blocking transcription factor binding to promoter sequences.
Consistent with our findings, other investigators have clearly demonstrated that DNA methylation can repress gene expression in a tissue-specific fashion by inhibiting binding of transcription factors to their cognate sequences (5, 6, 13, 27, 28) . For example, Ngo et al. (42) noted that methylation of the rat prolactin and growth hormone promoters correlated with decreased promoter activity. Furthermore, Ianello et al. (27) found that the core promoter of the Pdha-2 gene, which is sufficient for directing testis-specific expression, contains eight CpG dinucleotides; methylation of these sites and, in particular, a CpG site contained within a CREB/ATF site decreased activity of the wild-type promoter by 50%, suggesting that site-specific methylation can modulate gene expression.
Other mechanisms by which methylation can suppress gene expression include inhibition of transcription through methyl-C-binding proteins or by altering chromatin structure, thus influencing gene accessibility (7, 10, 16, 32, 41, 50) . To determine whether these latter mechanisms may account for our findings of NT/N expression in colon cancers, we performed locus accessibility assays using the restriction enzymes EcoR I and Msp I. No difference in the digestion patterns of either KM12C or KM20 DNA treated with these enzymes was noted, thus suggesting that these mechanisms of gene suppression do not appear applicable in this particular situation and lending further credence to the role of inhibition of transcription factor binding.
In conclusion, we have shown that DNA methylation plays a role in the silencing of NT/N gene expression in the colon cancer cell line KM20. Treatment with 5-azaC resulted in demethylation of the CpG sites located in the promoter region and resulted in NT/N expression. Methylation of the CpG dinucleotide contained site-blocked protein binding within a distal AP-1 and likely contributes to NT/N gene silencing associated with methylation. On the basis of our findings, we conclude that DNA methylation plays a role in NT/N gene silencing noted in a majority of colorectal cancers. Demethylation may then account for NT/N reexpression identified in ϳ25% of the cancers. Furthermore, we speculate that DNA methylation, in combination with transcription factors binding the promoter, may play a role in the temporal-and spatialspecific pattern of NT/N gene expression noted in the developing gastrointestinal tract.
